Program-Level Neoadjuvant Chemotherapy Use and 10-Year Survival in Advanced Ovarian Cancer - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Neoadjuvant Chemotherapy Strategies and a Decade of Survival Outcomes in Advanced Ovarian Cancer

  • By

  • Alex E. R. Powers

  • Gretchen Davis

  • Deshae Jenkins

  • Alicia Youssef

  • William Manning

  • Jason D. Wright

  • Nancy L. Keating

  • Amy Bregar

  • Alejandro Rauh-Hain

  • Alexander Melamed

  • September 17, 2026

Share

Objective:

To assess whether adoption of neoadjuvant chemotherapy (NACT) was associated with 10-year overall survival among patients with stage IIIC or IV epithelial ovarian cancer.

Approach:
  • Study Design: This comparative effectiveness study analyzed National Cancer Database records for patients diagnosed from January 1, 2004, through December 31, 2015.
  • Data Analysis: A difference-in-differences (DID) analysis compared changes in overall survival (OS) over time between programs with high and low NACT use. The analysis assessed associations and does not establish that NACT caused any observed changes.
Key Findings:
  • NACT use increased from 21.5% to 42.8% in high-use programs and from 20.3% to 22.7% in low-use programs.
  • Estimated 10-year survival probability increased in both high-use programs (from 15.6% to 20.0%) and low-use programs (from 15.1% to 19.1%).
  • The study found no significant association between NACT adoption and long-term survival probability or life expectancy.
Interpretation:

In this analysis, greater adoption of NACT was not associated with a significant difference in long-term survival. The findings do not establish that NACT has no effect on survival or that it is appropriate for every patient.

Limitations:
  • Changes in practices other than NACT may have affected the results and the validity of the comparison.
  • The data did not distinguish long-term survivors who were disease-free from those living with disease.
  • Classifying all patients who received initial chemotherapy as having undergone NACT may have introduced misclassification and biased the findings.
Conclusion:

Among patients with advanced-stage epithelial ovarian cancer in this study, increased NACT use was not associated with a significant difference in durable survival outcomes.

Sources:

Original Source(s)

Related Content